-
Nuocheng Jianhua's new SHP2 allosteric inhibitor ICP-189 new drug research application was accepted by the State Food and Drug Administration
Time of Update: 2021-08-05
On July 28, the biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) announced that the company's new protein tyrosine phosphatase SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP -189 New Drug Research (IND) application was accepted by the National Medical Products Administration (NMPA) .
-
Pfizer acquires part of ARV-471 equity for 2.4 billion
Time of Update: 2021-08-05
[News event]: Pfizer announced today that it will acquire a partial interest in the estrogen receptor PROTAC drug ARV-471 developed by Arvinas, a pioneer in protein degradation, with a down payment of 650 million and a stock subscription of 350 million, plus 1.
-
The successor of Yangtze River Pharmaceuticals confirmed Xu Haoyu as chairman and legal representative
Time of Update: 2021-08-05
On July 29, 2021, Yangtze River Pharmaceutical Group issued an announcement that according to the seventh meeting of the fifth board of directors of Yangtze River Pharmaceutical Group Co.
Sales Office clerk, provincial manager of the company, sell a Secretary; September 2005, he served as vice chairman of the Yangtze River Pharmaceutical Group Co.
-
Buchang Pharmaceutical Captopril Tablets Passed Consistency Evaluation
Time of Update: 2021-08-05
On July 28, Buchang Pharmaceutical issued an announcement stating that its holding subsidiary Liaoning Aoda Pharmaceutical Co.
("Liaoning Aoda") received the approval and issuance of the "Drugs of Captopril Tablets (25mg)" issued by the State Food and Drug Administration.
-
Kangchen Pharmaceutical Board Secretary Tang Zhisong resigns
Time of Update: 2021-08-05
On July 23, Kangchen Pharmaceutical issued an announcement stating that the company’s board of directors had recently received a written resignation report submitted by the company’s board secretary, Mr.
Tang Zhisong applied for his resignation from the position of secretary of the company's board of directors due to personal reasons.
-
WuXi AppTec subsidiary Hequan Pharmaceutical and Nuocheng Jianhua reach cooperation
Time of Update: 2021-08-05
According to the agreement, Hequan Pharmaceutical will become Nuocheng Jianhua's preferred CDMO partner, providing Nuocheng Jianhua's research and subsequent pipeline products (including small molecule drugs, peptides, oligonucleotides, complex chemical conjugate drugs, etc.
-
Maipu Medical's listing on the Shenzhen Stock Exchange rose 369%
Time of Update: 2021-08-05
On July 26, the official website of the Shenzhen Stock Exchange disclosed that Maipu Medical will be listed on the Growth Enterprise Market on July 26, 2021 .
14 yuan per share, the new shares raised 250 million yuan, and the total share capital after the issuance was 66,062,951 shares .
-
Launch of Recombinant Human Coagulation Factor VIII for Injection and Nuoyi®
Time of Update: 2021-08-04
July 31, 2021, developed by Novo Nordisk production of injection of recombinant human coagulation factor Ⅷ promise Yi ® officially listed in China, for the treatment of adults and children with hemophilia .
-
CD47 is the next PD-1?
Time of Update: 2021-08-04
In order to avoid the problem of hematological toxicity, the company uses a unique antigen-binding epitope to retain the promotion of macrophage activity and anti-tumor efficacy, while reducing the combination of drugs and red blood cells, and reducing side effects such as anemia after antibody injection .
-
Luye Pharma's next-generation VMAT2 inhibitor submits clinical trial application in the U.S.
Time of Update: 2021-08-04
On August 2, Luye Pharmaceutical Group announced that its self-developed new generation of vesicle monoamine transporter 2 (VMAT2) inhibitor LY03015 has submitted a clinical trial application in the United States and will soon enter the phase I clinical phase .
-
Sichuan Huiyu enters the bureau with 2 billion injections to challenge Hengrui's leading position
Time of Update: 2021-08-03
Figure 2: The competitive landscape of cisatracurium enterprises in 2020 Source: Mi Nei. com, China's public medical institutions terminal competition pattern From the perspective of corporate competition, Hengrui is currently leading this product, with a market share of 72% in 2020, and Aspen, the original research pharmaceutical company, only accounts for 0.
-
Hisun Pharmaceutical Receives Approval for Supplementary Application for Amlodipine and Atorvastatin Calcium Tablets
Time of Update: 2021-08-03
The Food and Drug Administration submitted a drug production technology transfer application for amlodipine and atorvastatin calcium tablets, which was approved in July 2021, and the trade name of "DaDa Yi" was retained .
-
Throwing a license in of US$338 million to understand the "Zai Lab Model" in one article
Time of Update: 2021-08-03
Some time ago, Zai Lab and Mirati Therapeutics, a precision oncology company in the clinical stage, announced that they have reached a cooperation and licensing agreement for the small molecule KRAS G12C inhibitor adagrasib in Greater China (Mainland China, Hong Kong, Macau and Taiwan) .
-
Equity transfer + Dingzeng Boya Biotech's controlling shareholder will be changed to China Resources Pharmaceutical Holdings
Time of Update: 2021-08-03
On July 15th, Boya Biotechnology learned that the registration procedures for this share transfer have been completed recently, and China Resources Pharmaceutical Holdings has become the company’s largest shareholder, with a total of 126,381,618 shares of the company (accounting for the proportion of the company’s total share capital before this fixed increase) 29.
-
China Resources Biotech, a subsidiary of China Resources Pharmaceuticals, and Biocytometer start comprehensive strategic cooperation
Time of Update: 2021-08-03
The strategic cooperation between the two pharmaceutical companies is intended to develop innovative drugs for multiple targets selected by both parties in the field of oncology and self-immunity indications .
-
Pandora's Box of Cannibals-Kuru and Ruan Virus
Time of Update: 2021-08-02
In fact, acquired prion diseases represented by Kuru only account for about 5% .
One of the main characteristics that distinguishes TSE from other neurodegenerative diseases caused by protein misfolding and aggregation is their infectivity between individuals of the same species and other species .
Kuru, the First Human Prion Disease.
-
Roche Announces Phase IIIb Clinical Trial Data of Hemlibra in the Treatment of Hemophilia A
Time of Update: 2021-08-02
This analysis shows that in adults and adolescents with hemophilia A who produce factor VIII inhibitors in the body, long-term Hemlibra treatment has not found new safety signals .
The final analysis of the STASEY study included data on 193 hemophilia A patients who produced factor VIII inhibitors in their bodies.
-
Step length enters 700 million cardiovascular drugs original research drug market is hit again
Time of Update: 2021-08-02
Sales of olmesartan medoxomil tablets in physical pharmacies in Chinese cities in recent years (unit: 100 million yuan) Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern Meinenet data shows that in 2020, the total sales of olmesartan medoxomil tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals exceed 700 million.
-
TDM1 treatment of six-line advanced breast cancer patients, MRG002 treatment rapid PR MRG002 brings new hope to HER2-positive breast cancer patients
Time of Update: 2021-08-02
A multi-center, open-label, dose escalation and expanded phase I study of Lepu Biologics' new anti-HER2 antibody drug conjugate (ADC) MRG002 for the treatment of HER2-positive advanced solid tumors is in full swing .
-
2021 Shenzhen International Medical Protective Products Exhibition will be held soon
Time of Update: 2021-08-01
Medical Network, July 22, the 2021 Shenzhen International Medical Protective Products Exhibition will be held at the Shenzhen Convention and Exhibition Center from August 18th to August 20th. This e
